Evidence map›Paper›PMID 31413138›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2019

GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine.

Na-Ra Lee, Guangrong Zheng, Markos Leggas, Venumadhav Janganati, Justin R Nickell, Peter A Crooks, Michael T Bardo, Linda P Dwoskin

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Na-Ra LeeDepartment of Pharmaceutical Sciences, College of Pharmacy (N.-R.L., M.L., J.R.N., L.P.D.), and Department of Psychology, College of Arts & Sciences (M.T.B.), University of Kentucky, Lexington, Kentucky; Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, Florida (G.Z.); and Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas (V.J., P.A.C.).
Guangrong ZhengDepartment of Pharmaceutical Sciences, College of Pharmacy (N.-R.L., M.L., J.R.N., L.P.D.), and Department of Psychology, College of Arts & Sciences (M.T.B.), University of Kentucky, Lexington, Kentucky; Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, Florida (G.Z.); and Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas (V.J., P.A.C.).
Markos LeggasDepartment of Pharmaceutical Sciences, College of Pharmacy (N.-R.L., M.L., J.R.N., L.P.D.), and Department of Psychology, College of Arts & Sciences (M.T.B.), University of Kentucky, Lexington, Kentucky; Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, Florida (G.Z.); and Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas (V.J., P.A.C.).
Venumadhav JanganatiDepartment of Pharmaceutical Sciences, College of Pharmacy (N.-R.L., M.L., J.R.N., L.P.D.), and Department of Psychology, College of Arts & Sciences (M.T.B.), University of Kentucky, Lexington, Kentucky; Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, Florida (G.Z.); and Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas (V.J., P.A.C.).
Justin R NickellDepartment of Pharmaceutical Sciences, College of Pharmacy (N.-R.L., M.L., J.R.N., L.P.D.), and Department of Psychology, College of Arts & Sciences (M.T.B.), University of Kentucky, Lexington, Kentucky; Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, Florida (G.Z.); and Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas (V.J., P.A.C.).
Peter A CrooksDepartment of Pharmaceutical Sciences, College of Pharmacy (N.-R.L., M.L., J.R.N., L.P.D.), and Department of Psychology, College of Arts & Sciences (M.T.B.), University of Kentucky, Lexington, Kentucky; Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, Florida (G.Z.); and Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas (V.J., P.A.C.).
Michael T BardoDepartment of Pharmaceutical Sciences, College of Pharmacy (N.-R.L., M.L., J.R.N., L.P.D.), and Department of Psychology, College of Arts & Sciences (M.T.B.), University of Kentucky, Lexington, Kentucky; Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, Florida (G.Z.); and Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas (V.J., P.A.C.).
Linda P DwoskinDepartment of Pharmaceutical Sciences, College of Pharmacy (N.-R.L., M.L., J.R.N., L.P.D.), and Department of Psychology, College of Arts & Sciences (M.T.B.), University of Kentucky, Lexington, Kentucky; Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, Florida (G.Z.); and Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas (V.J., P.A.C.) ldwoskin@uky.edu.
University of Kentucky · USUniversity of Arkansas for Medical Sciences · USUniversity of Florida · US

Funding

Kentucky Center for Clinical and Translational ScienceUL1TR001998 · NCATS · UNIVERSITY OF KENTUCKY · PI HARTMANN, KATHERINE E, KERN, PHILIP A · 2016 to 2025
$34.2M
Training in Drug Abuse Related Research.T32DA016176 · NIDA · UNIVERSITY OF KENTUCKY · PI DWOSKIN, LINDA P · 2004 to 2020
$4.0M
Development of Novel Therapies or Methamphetamine AbuseU01DA013519 · NIDA · UNIVERSITY OF KENTUCKY · PI DWOSKIN, LINDA P · 2012 to 2016
$3.2M
Development of Novel Therapeutics for Methamphetamine AbuseU01DA043908 · NIDA · UNIVERSITY OF KENTUCKY · PI DWOSKIN, LINDA P · 2018 to 2020
$1.9M
NCATS NIH HHS UL1 TR001998NIDA NIH HHS T32 DA016176NIDA NIH HHS U01 DA013519NIDA NIH HHS U01 DA043908
6 · The paper itself

Abstract

Despite escalating methamphetamine use and high relapse rates, pharmacotherapeutics for methamphetamine use disorders are not available. Our iterative drug discovery program had found that

Indexed as

AnimalsBehavior, AddictiveBrainDopamineDopamine Uptake InhibitorsDose-Response Relationship, DrugLocomotionMaleMethamphetamineRatsRats, Sprague-DawleySelf AdministrationSynaptosomesVesicular Monoamine Transport ProteinsDopamineDopamine Uptake InhibitorsMethamphetamineSlc18a2 protein, ratVesicular Monoamine Transport Proteins

Identifiers

PMID31413138
PMCPMC6863457
OpenAlexW2967327778

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.